My5-FU
BSA dosing results in sub-target 5-FU levels in the majority of patients. TDM-guided dosing can move 5-FU levels into the target range. Optimal dosing of 5-FU is associated with increased efficacy and reduced toxicity.
- Personalize dose to personalize medicine
- Reduce the risk of under dosing
- Optimize each individual patient’s dose based on their drug exposure levels
1. Saam, et al. 2011. Clin Colorectal Cancer; 10: 203-206.
2. Zhou, et al. 2021. Med Sci Monit; 27:e929474
*Product available with CE Mark
Busulfan
Around one-third of patients don’t achieve target busulfan exposure when dosed using BSA. TDM based dosing may ensure optimal exposure is achieved, which is essential for successful hematopoietic stem cell transplantation outcomes.1
Busulfan TDM decreases incidence rates of:
- Disease relapse 3 years post transplantation2
1. Palmer, et al. 2016. Biol Blood Marrow Transplant; 22: 1915-1925.
2. Slattery, et al. 1997. Blood; 89: 3055-3060.
* Product available with CE Mark
